Voyager Therapeutics (NASDAQ:VYGR) Trading Down 2.9%

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) dropped 2.9% during trading on Wednesday . The stock traded as low as $7.74 and last traded at $7.75. Approximately 163,179 shares were traded during mid-day trading, a decline of 82% from the average daily volume of 927,578 shares. The stock had previously closed at $7.98.

Wall Street Analysts Forecast Growth

VYGR has been the subject of several research reports. HC Wainwright initiated coverage on shares of Voyager Therapeutics in a research report on Tuesday, March 19th. They issued a “buy” rating and a $30.00 price target for the company. Citigroup started coverage on shares of Voyager Therapeutics in a report on Thursday, March 7th. They issued a “buy” rating and a $16.00 price target for the company. Wells Fargo & Company upgraded shares of Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $9.00 to $14.00 in a report on Tuesday, January 2nd. Guggenheim began coverage on shares of Voyager Therapeutics in a report on Tuesday, March 26th. They issued a “buy” rating and a $22.00 price target for the company. Finally, StockNews.com raised shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, March 9th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $19.33.

Voyager Therapeutics Trading Up 2.1 %

The stock has a market capitalization of $418.65 million, a price-to-earnings ratio of 2.44 and a beta of 0.96. The stock’s 50 day moving average is $8.80 and its 200 day moving average is $7.95.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Wednesday, February 28th. The company reported $1.25 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $1.84. Voyager Therapeutics had a net margin of 52.93% and a return on equity of 63.89%. The company had revenue of $90.06 million for the quarter, compared to analysts’ expectations of $4.95 million. On average, sell-side analysts anticipate that Voyager Therapeutics, Inc. will post -1.64 EPS for the current year.

Institutional Investors Weigh In On Voyager Therapeutics

Several hedge funds have recently modified their holdings of VYGR. Gladius Capital Management LP acquired a new stake in shares of Voyager Therapeutics in the third quarter worth approximately $25,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Voyager Therapeutics in the second quarter worth approximately $30,000. AJOVista LLC acquired a new stake in shares of Voyager Therapeutics in the fourth quarter worth approximately $39,000. UBS Group AG acquired a new stake in shares of Voyager Therapeutics in the first quarter worth approximately $39,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in Voyager Therapeutics in the fourth quarter valued at approximately $43,000. 48.03% of the stock is owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.